Aller au contenu principal
Accès ouvert déclaré 2026 article

Role of Botulinum toxin injection in the treatment of spasmodic dysphonia: Experience in Bangladesh Medical University

0Citations signalées — pas une note de qualité
3Institutions déclarées
1Pays d’affiliation déclarés

Résumé fourni par la source

Background: Spasmodic dysphonia (SD) is a focal dystonia and adductor SD is the commonest form. The standard treatment for adductor SD is EMG-guided, transcutaneous injections of botulinum toxin into the thyroarytenoid muscle. Methods: This is a prospective study on patients with adductor spasmodic dysphonia done in Bangladesh Medical University, Dhaka from January 2020 to January 2023. All of the patients were studied with a complete head and neck and neurologic examination, fiberoptic laryngostroboscopy, and a speech evaluation including the Universal spasmodic dysphonia rating scale and VHI. Proper counselling regarding the results & possible complication was done. All patients received botulinum toxin injections into the thyroarytenoid muscles under fiberoptic laryngostroboscopy guidance, post injections following results were recorded. Results: The median duration of symptoms prior to diagnosis was 12 months: all were adductor in type. The average age at onset was 44 years. The time for botulinum toxin to take effect averaged 3 days (peak effect, 7 days). The patients received substantialrelief from their SD symptoms, an average functional improvement of 40%. Patients’ best voice was achieved within one week and persisted for an average of 14 weeks. Side effects from the injections included mild breathiness (68%) and mild choking onfluid (56%). After injection, decreased potential for volume was a common complaint. Almost all of the patients returned for repeat injections when the benefit diminished (After 12-16 weeks). Conclusion: Botulinum toxin therapy has become the standard care for the treatment of SD. An acceptable and flexible treatment plan to produce a balance between decreased spasms and loss of function must be developed for each patient. Bangladesh J Otorhinolaryngol 2025; 31(2): 52-61

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Role of Botulinum toxin injection in the treatment of spasmodic dysphonia: Experience in Bangladesh Medical University
Date Crossref
21/04/2026
Éditeur
Bangladesh Academy of Sciences
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.

Institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Sujets associés

Voice and Speech DisordersBotulinum Toxin and Related Neurological DisordersDysphagia Assessment and Management

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.